



	Dr. Vinay C MD (Pathology Chairman & Co		MD CEO & Consultant	m Chopra D (Pathology) ht Pathologist	
NAME : Mrs.	PRABHJOT KAUR				
AGE/ GENDER : 37 YRS/FEMALE]	PATIENT ID	: 1720697	
COLLECTED BY :		1	REG. NO./LAB NO.	: 042501100002	
REFERRED BY : BARCODE NO. : A1260284		REGISTRATION DATE COLLECTION DATE		: 10/Jan/2025 10:00 AM	
				: 10/Jan/2025 11:26AM	
	DIAGNOSTIC SHAHBAD		REPORTING DATE	: 10/Jan/2025 12:59PM	
CLIENT ADDRESS : 6349	/1, NICHOLSON ROAD,	AMBALA CANTT			
Test Name		Value	Unit	Biological Reference interval	
	CUNI	CAT CHEMIST	RY/BIOCHEMIST	'RV	
	CLINI		FILE : BASIC	NI	
CHOLESTEROL TOTAL: SEI		146.34		OPTIMAL: < 200.0	
by CHOLESTEROL OXIDASE PA		140.34	mg/dL	BORDERLINE HIGH: 200.0 -	
				239.0	
				HIGH CHOLESTEROL: > OR = 240.0	
TRIGLYCERIDES: SERUM		100.07	mg/dL	OPTIMAL: < 150.0	
by GLYCEROL PHOSPHATE OX	IDASE (ENZYMATIC)))	Ū	BORDERLINE HIGH: 150.0 -	
				199.0 HIGH: 200.0 - 499.0	
				VERY HIGH: $> OR = 500.0$	
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION		36.5	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0	
by GELLOTIVE INTIBILION				60.0	
				HIGH HDL: $> OR = 60.0$	
LDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY		89.83	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0	
, or 2002				BORDERLINE HIGH: 130.0 -	
				159.0	
				HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0	
NON HDL CHOLESTEROL: SERUM		109.84	mg/dL	OPTIMAL: < 130.0	
by CALCULATED, SPECTROPH	DTOMETRY			ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 -	
				189.0	
				HIGH: 190.0 - 219.0	
VI DI CUOI Εςτεσοι · ςερι	IM	20.01	ma/di	VERY HIGH: > OR = 220.0 0.00 - 45.00	
VLDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY		20.01	mg/dL	0.00 - 43.00	
TOTAL LIPIDS: SERUM by CALCULATED, SPECTROPHOTOMETRY		392.75	mg/dL	350.00 - 700.00	
CHOLESTEROL/HDL RATIO		4.01	RATIO	LOW RISK: 3.30 - 4.40	
by CALCULATED, SPECTROPHOTOMETRY				AVERAGE RISK: 4.50 - 7.0	

KOS Diagnostic Lab (A Unit of KOS Healthcare)



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: Ilnd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.





		Chopra y & Microbiology) ionsultant Pathologist	Dr. Yugam MD CEO & Consultant	(Pathology)
NAME	: Mrs. PRABHJOT KAUR			
AGE/ GENDER	: 37 YRS/FEMALE	PA	FIENT ID	: 1720697
COLLECTED BY	:	RE	G. NO./LAB NO.	: 042501100002
REFERRED BY	:	RE	GISTRATION DATE	: 10/Jan/2025 10:00 AM
BARCODE NO.	: A1260284	CO	LLECTION DATE	: 10/Jan/2025 11:26AM
CLIENT CODE.	: KOS DIAGNOSTIC SHAHBA	AD RE	PORTING DATE	: 10/Jan/2025 12:59PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROA	D, AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
LDL/HDL RATIO: S by calculated, spe		2.46	RATIO	MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY		2.74 ^L	RATIO	3.00 - 5.00

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

End Of Report ***





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com

